Clinical Trial Update: A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa [Phase 1, Phase 2]

View source ↗

Summary

This document reports a first-in-human, Phase 1/2 study of CPK850 for RLBP1-related Retinitis Pigmentosa, sponsored by Novartis, which is currently active but n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinitis Pigmentosa

Drugs mentioned

• CPK850

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Retinitis Pigmentosa | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING